Autografts are produced using material harvested from the patient without creation of a new wound. For example, material is harvested from the patient's very wound to which the autograft is to be applied.

Provided are live, artificial, skin substitute products and methods of making and using the same, such as for wound treatment and compound testing, including compound testing for efficacy, toxicity, penetration, irritation and/or metabolism testing of drug candidates or compositions such as cosmetics. Described herein is an artificial mammalian skin substitute product, comprising: (a) optionally, but in some embodiments preferably, a first (“hypodermis-like”) layer comprising live mammalian adipocytes (e.g., induced pre-adipocytes) in a first hydrogel carrier; (b) a second (“dermis-like”) layer contacting or directly contacting the first layer and comprising live mammalian fibroblast cells and' live mammalian follicle dermal papilla cells in combination in a second hydrogel carrier; (c) a third (“epidermis-like”) layer contacting or directly contacting the second layer (i.e., on the opposite side thereof as the first layer, so that the second layer is sandwiched between the first and third layers when the first layer is present), the third layer comprising live mammalian keratinocytes and live mammalian melanocytes in combination in a third hydrogel carrier.

Provided are live, artificial, skin substitute products and methods of making and using the same, such as for wound treatment and compound testing, including compound testing for efficacy, toxicity, penetration, irritation and/or metabolism testing of drug candidates or compositions such as cosmetics. Described herein is an artificial mammalian skin substitute product, comprising: (a) optionally, but in some embodiments preferably, a first (“hypodermis-like”) layer comprising live mammalian adipocytes (e.g., induced pre-adipocytes) in a first hydrogel carrier; (b) a second (“dermis-like”) layer contacting or directly contacting the first layer and comprising live mammalian fibroblast cells and' live mammalian follicle dermal papilla cells in combination in a second hydrogel carrier; (c) a third (“epidermis-like”) layer contacting or directly contacting the second layer (i.e., on the opposite side thereof as the first layer, so that the second layer is sandwiched between the first and third layers when the first layer is present), the third layer comprising live mammalian keratinocytes and live mammalian melanocytes in combination in a third hydrogel carrier.

A method for preparing a conductive biomimetic skin scaffold material with self-repairing function includes the following steps: adding 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride to a homogeneous dispersion of acidified carbon nanotubes, poly(3,4-ethylenedioxythiophene) polystyrene sulfonate (PEDOT:PSS), and gelatin to cross-link to obtain a conductive composite colloid; and injecting the conductive composite colloid into a mold, aging at −4-4° C. for 12-24 hours, and then soaking in a phosphate-buffered saline (PBS) solution with a pH of 7.0-7.4 for 12-24 hours to obtain the conductive biomimetic skin scaffold material.

A method for preparing a conductive biomimetic skin scaffold material with self-repairing function includes the following steps: adding 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride to a homogeneous dispersion of acidified carbon nanotubes, poly(3,4-ethylenedioxythiophene) polystyrene sulfonate (PEDOT:PSS), and gelatin to cross-link to obtain a conductive composite colloid; and injecting the conductive composite colloid into a mold, aging at −4-4° C. for 12-24 hours, and then soaking in a phosphate-buffered saline (PBS) solution with a pH of 7.0-7.4 for 12-24 hours to obtain the conductive biomimetic skin scaffold material.

A biocompatible, resorbable biphasic collagen membrane having a first area of relatively higher tensile strength and stiffness and lower porosity and a second area of relatively lower tensile strength and stiffness and higher porosity, and a method of manufacturing the such a membrane.

A biocompatible, resorbable biphasic collagen membrane having a first area of relatively higher tensile strength and stiffness and lower porosity and a second area of relatively lower tensile strength and stiffness and higher porosity, and a method of manufacturing the such a membrane.

The present invention is directed to a process for making a tissue regeneration matrix. The process comprises providing a collagen-tropoelastin dispersion; freeze-drying the dispersion to provide a porous freeze-dried matrix; and then crosslinking the porous freeze-dried matrix. The present invention is also directed to a tissue regeneration matrix prepared by the process.

The present invention provides a method for manufacturing fungal pharmaceutical composition, used for extracting a glycosaminoglycan fiber from a fungal cell wall. Differing from the glycosaminoglycan fiber produced by using a fabrication method proposed by Taiwan patent No. 442496 showing many drawbacks including low extraction percentage, coarse fiber, and having light-yellow color, the glycosaminoglycan fiber manufactured by using this novel method reveals the advantages of high extraction percentage, fine fibers, and showing white color. So that, the novel glycosaminoglycan fiber produced by using the present invention's method is suitable for being processed to an excipient. Moreover, because a variety of experimental results have proved that the glycosaminoglycan fiber produced by using the present invention's method possesses good adsorption ability of tissue fluid and moisture retention ability, this novel glycosaminoglycan fiber is also suitable for being processed to a skin dressing, an artificial skin, or a hydrate mask.

The present invention provides a method for manufacturing fungal pharmaceutical composition, used for extracting a glycosaminoglycan fiber from a fungal cell wall. Differing from the glycosaminoglycan fiber produced by using a fabrication method proposed by Taiwan patent No. 442496 showing many drawbacks including low extraction percentage, coarse fiber, and having light-yellow color, the glycosaminoglycan fiber manufactured by using this novel method reveals the advantages of high extraction percentage, fine fibers, and showing white color. So that, the novel glycosaminoglycan fiber produced by using the present invention's method is suitable for being processed to an excipient. Moreover, because a variety of experimental results have proved that the glycosaminoglycan fiber produced by using the present invention's method possesses good adsorption ability of tissue fluid and moisture retention ability, this novel glycosaminoglycan fiber is also suitable for being processed to a skin dressing, an artificial skin, or a hydrate mask.